Kids v Cancer

New Cancer Drug, Three More for Rare Pediatric Diseases Approved, and a Voucher Sells for $95 Million

A new drug for neuroblastoma and three more drugs for rare pediatric diseases approved during Thanksgiving week, earning the vouchers under the Creating Hope Act. more→

Congress Provides Short Term Reauthorization for the Pediatric Voucher Program

The House of Representatives passed the Creating Hope Reauthorization Act to extend the rare pediatric disease voucher program for four years. more→

Creating Hope: In Support of the Creating Hope Reauthorization Act, Making the Rare Pediatric Disease Priority Review Voucher Program Permanent (Testimony by Nancy Goodman)

Testimony before the Health Subcommittee of the U.S. House of Representatives Energy and
Commerce Committee, July 29, 2020. Nancy Goodman, Founder of Kids v Cancer more→

RACE for Children Act Could Substantially Increase Studies of Pediatric Cancer Drugs (Cancer Therapy Advisor)

The Research to Accelerate Cures and Equity (RACE) for Children Act has the potential to substantially increase the number of required pediatric studies for novel anticancer drugs, according to an analysis of previously approved agents and RACE criteria. more→

FDA Publishes RACE for Children Act Draft Guidance for Industry

Publication of the guidance is the next step in implementation of the RACE for Children Act, which addresses drug development for rare pediatric cancers. It includes lists of molecular targets for which pediatric studies are required or waived. more→

Another Voucher Sold for $95 Million

Priority review vouchers, created under the Creating Hope Act of 2012 and awarded by FDA since 2014, have brought to market 19 new rare pediatric disease medicines. more→